Abstract: The present invention provides transgenic Brassica events LBFLFK and LBFDAU and progeny thereof, and cells, seeds, plants comprising DNA diagnostic for these events. The invention also provides artificial oligonucleotide primers and probes that are diagnostic for the LBFLFK and LBFDAU events and their progeny in a sample, and methods for detecting the presence of the LBFLFK and LBFDAU events and their progeny in a sample. The invention further provides oil and commodity products derived from the LBFLFK and LBFDAU events.

Abstract: T-DNA for expression of a target gene in a plant, wherein the T-DNA comprises a left and a right border element and at least one expression cassette comprising a promoter, operatively linked thereto a target gene, and downstream thereof a terminator, wherein the length of the T-DNA, measured from left to right border element and comprising the target gene, has a length of at least 30000 bp.

Abstract: T-DNA for expression of a target gene in a plant, wherein the T-DNA comprises a left and a right border element and at least one expression cassette comprising a promoter, operatively linked thereto a target gene, and downstream thereof a terminator, wherein the length of the T-DNA, measured from left to right border element and comprising the target gene, has a length of at least 30000 bp.

Abstract: The present invention provides transgenic Brassica events LBFLFK and LBFDAU and progeny thereof, and cells, seeds, plants comprising DNA diagnostic for these events. The invention also provides artificial oligonucleotide primers and probes that are diagnostic for the LBFLFK and LBFDAU events and their progeny in a sample, and methods for detecting the presence of the LBFLFK and LBFDAU events and their progeny in a sample. The invention further provides oil and commodity products derived from the LBFLFK and LBFDAU events.

Abstract: The present invention provides transgenic Brassica events LBFLFK and LBFDAU and progeny thereof, and cells, seeds, plants comprising DNA diagnostic for these events. The invention also provides artificial oligonucleotide primers and probes that are diagnostic for the LBFLFK and LBFDAU events and their progeny in a sample, and methods for detecting the presence of the LBFLFK and LBFDAU events and their progeny in a sample. The invention further provides oil and commodity products derived from the LBFLFK and LBFDAU events.

Abstract: The present invention provides transgenic Brassica events LBFLFK and LBFDAU and progeny thereof, and cells, seeds, plants comprising DNA diagnostic for these events. The invention also provides artificial oligonucleotide primers and probes that are diagnostic for the LBFLFK and LBFDAU events and their progeny in a sample, and methods for detecting the presence of the LBFLFK and LBFDAU events and their progeny in a sample. The invention further provides oil and commodity products derived from the LBFLFK and LBFDAU events.

Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: The present invention provides biomarkers and a method for differentiating between NASH and NAFLD in a subject.

Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: The present invention relates to screening methods for diabetes drugs. In particular, the invention concerns a method for identifying a drug against diabetes comprising determining the amount of glyoxylate in a test sample of a subject suffering from diabetes or a diabetes-like condition, wherein said test sample has been taken after the subject has been brought into contact with a compound suspected to be a drug against diabetes and comparing the determined amount to a reference amount for glyoxylate, whereby a compound being a drug against diabetes is identified.

Abstract: The present invention relates to the field of diagnostic measures. Specifically, it contemplates a method for assessing whether gastric bypass therapy was successful in a subject, a method of predicting whether gastric bypass therapy will be beneficial for a subject in need thereof, and a method of diagnosing whether a supportive therapy accompanying gastric bypass has beneficial effects on a subject in need thereof. Further provided are diagnostic methods for diabetes and body lean mass. Furthermore, the invention relates to a method for identifying a treatment against diabetes and/or obesity.

Abstract: A method for diagnosing diabetes or a predisposition for diabetes is provided, which comprises determining the amount of glyoxylate in a test sample of a subject suspected to suffer from diabetes or to have a predisposition for diabetes and comparing said amount to a references, whereby diabetes or a predisposition for diabetes is to be diagnosed. Further, the use of glyoxylate or a detection agent for glyoxylate for diagnosing diabetes or a predisposition for diabetes is provided. Moreover, a device and a kit for diagnosing diabetes or a predisposition for diabetes are also provided.

Abstract: The invention relates to a plant seed oil, comprising arachidonic acid comprising approximately 7 to approximately 26 percent by weight of the total fatty acid content, the ratio of the percentages by weight of arachidonic acid to gamma-linolenic acid being approximately 1:1 to approximately 5:1 and the ratio of the percentages by weight of arachidonic acid to dihomo-gamma-linolenic acid being approximately 1:1 to approximately 5:1. The invention additionally relates to processes for the production of this plant seed oil and formulations and uses of the plant seed oil. In particular, the invention also makes available foodstuffs and baby food that contain the plant seed oil mentioned.

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a liver disease in a subject and a method of differentiating between NASH and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: The present invention relates to the field of diagnostic measures. Specifically, it contemplates a method for assessing whether gastric bypass therapy was successful in a subject, a method of predicting whether gastric bypass therapy will be beneficial for a subject in need thereof, and a method of diagnosing whether a supportive therapy accompanying gastric bypass has beneficial effects on a subject in need thereof. Further provided are diagnostic methods for diabetes and body lean mass. Furthermore, the invention relates to a method for identifying a treatment against diabetes and/or obesity.

Abstract: The invention relates to a plant seed oil, comprising arachidonic acid comprising approximately 7 to approximately 26 percent by weight of the total fatty acid content, the ratio of the percentages by weight of arachidonic acid to gamma-linolenic acid being approximately 1:1 to approximately 5:1 and the ratio of the percentages by weight of arachidonic acid to dihomo-gamma-linolenic acid being approximately 1:1 to approximately 5:1. The invention additionally relates to processes for the production of this plant seed oil and formulations and uses of the plant seed oil. In particular, the invention also makes available foodstuffs and baby food that contain the plant seed oil mentioned.